Jonathan Wolleben
Stock Analyst at JMP Securities
(4.28)
# 373
Out of 4,874 analysts
201
Total ratings
49.51%
Success rate
15.95%
Average return
Main Sectors:
Stocks Rated by Jonathan Wolleben
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RYTM Rhythm Pharmaceuticals | Reiterates: Market Outperform | $84 | $61.45 | +36.71% | 3 | Jun 26, 2025 | |
| DBVT DBV Technologies | Reiterates: Market Outperform | $21 | $9.21 | +128.01% | 15 | Jun 26, 2025 | |
| SKYE Skye Bioscience | Reiterates: Market Outperform | $15 | $4.25 | +252.94% | 3 | Jun 24, 2025 | |
| GPCR Structure Therapeutics | Reiterates: Market Outperform | $89 | $21.08 | +322.20% | 9 | Jun 23, 2025 | |
| AURA Aura Biosciences | Reiterates: Market Outperform | $19 | $6.29 | +202.07% | 9 | May 23, 2025 | |
| CLSD Clearside Biomedical | Reiterates: Market Outperform | $5 | $0.81 | +516.52% | 11 | May 16, 2025 | |
| MIRM Mirum Pharmaceuticals | Maintains: Market Outperform | $74 → $76 | $50.52 | +50.44% | 10 | May 9, 2025 | |
| MDGL Madrigal Pharmaceuticals | Reiterates: Market Outperform | $443 | $299.51 | +47.91% | 12 | Apr 24, 2025 | |
| MBX MBX Biosciences | Initiates: Market Outperform | $38 | $11.29 | +236.58% | 1 | Apr 10, 2025 | |
| ALT Altimmune | Reiterates: Market Outperform | $25 | $3.61 | +592.52% | 12 | Apr 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $19 | $11.50 | +65.22% | 3 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $61 | $55.22 | +10.48% | 11 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $22 → $19 | $9.46 | +100.85% | 17 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $55 | $17.44 | +215.37% | 11 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $18 | $9.66 | +86.34% | 8 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $26 | $5.44 | +377.94% | 2 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $92 → $91 | $29.99 | +203.43% | 14 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $9 | $2.21 | +307.24% | 8 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $55 → $50 | $41.11 | +21.62% | 1 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $90 | $81.50 | +10.43% | 1 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $133.72 | - | 1 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $8 | $2.16 | +270.37% | 7 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Accumulate | $420 → $485 | $775.90 | -37.49% | 1 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $48 → $32 | $8.70 | +267.82% | 8 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $25 | $3.08 | +711.69% | 11 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $8 | $0.36 | +2,106.90% | 11 | Apr 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $24 | $26.60 | -9.77% | 1 | May 12, 2023 |
Rhythm Pharmaceuticals
Jun 26, 2025
Reiterates: Market Outperform
Price Target: $84
Current: $61.45
Upside: +36.71%
DBV Technologies
Jun 26, 2025
Reiterates: Market Outperform
Price Target: $21
Current: $9.21
Upside: +128.01%
Skye Bioscience
Jun 24, 2025
Reiterates: Market Outperform
Price Target: $15
Current: $4.25
Upside: +252.94%
Structure Therapeutics
Jun 23, 2025
Reiterates: Market Outperform
Price Target: $89
Current: $21.08
Upside: +322.20%
Aura Biosciences
May 23, 2025
Reiterates: Market Outperform
Price Target: $19
Current: $6.29
Upside: +202.07%
Clearside Biomedical
May 16, 2025
Reiterates: Market Outperform
Price Target: $5
Current: $0.81
Upside: +516.52%
Mirum Pharmaceuticals
May 9, 2025
Maintains: Market Outperform
Price Target: $74 → $76
Current: $50.52
Upside: +50.44%
Madrigal Pharmaceuticals
Apr 24, 2025
Reiterates: Market Outperform
Price Target: $443
Current: $299.51
Upside: +47.91%
MBX Biosciences
Apr 10, 2025
Initiates: Market Outperform
Price Target: $38
Current: $11.29
Upside: +236.58%
Altimmune
Apr 2, 2025
Reiterates: Market Outperform
Price Target: $25
Current: $3.61
Upside: +592.52%
Mar 26, 2025
Reiterates: Market Outperform
Price Target: $19
Current: $11.50
Upside: +65.22%
Mar 10, 2025
Reiterates: Market Outperform
Price Target: $61
Current: $55.22
Upside: +10.48%
Mar 4, 2025
Maintains: Market Outperform
Price Target: $22 → $19
Current: $9.46
Upside: +100.85%
Mar 3, 2025
Reiterates: Market Outperform
Price Target: $55
Current: $17.44
Upside: +215.37%
Mar 3, 2025
Reiterates: Market Outperform
Price Target: $18
Current: $9.66
Upside: +86.34%
Mar 3, 2025
Reiterates: Market Outperform
Price Target: $26
Current: $5.44
Upside: +377.94%
Feb 28, 2025
Maintains: Market Outperform
Price Target: $92 → $91
Current: $29.99
Upside: +203.43%
Dec 19, 2024
Reiterates: Market Outperform
Price Target: $9
Current: $2.21
Upside: +307.24%
Dec 18, 2024
Maintains: Market Outperform
Price Target: $55 → $50
Current: $41.11
Upside: +21.62%
Dec 16, 2024
Reiterates: Market Outperform
Price Target: $90
Current: $81.50
Upside: +10.43%
Dec 16, 2024
Reiterates: Market Perform
Price Target: n/a
Current: $133.72
Upside: -
Dec 12, 2024
Reiterates: Market Outperform
Price Target: $8
Current: $2.16
Upside: +270.37%
Nov 13, 2024
Downgrades: Accumulate
Price Target: $420 → $485
Current: $775.90
Upside: -37.49%
Aug 15, 2024
Maintains: Market Outperform
Price Target: $48 → $32
Current: $8.70
Upside: +267.82%
May 31, 2024
Reiterates: Market Outperform
Price Target: $25
Current: $3.08
Upside: +711.69%
Apr 19, 2024
Reiterates: Market Outperform
Price Target: $8
Current: $0.36
Upside: +2,106.90%
May 12, 2023
Maintains: Outperform
Price Target: $25 → $24
Current: $26.60
Upside: -9.77%